Stay in the know

Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank of America, Morgan Stanley, Raymond James, UBS, & Wells Fargo. [...]

Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc's (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation [...]

Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.” Link: https://www.meipharma.com/press-releases/mei-pharma-announces-closing-public-offering-common-stock-0

Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities

Laidlaw Capital Markets is pleased to have Co-Managed the $655,000,000 Guggenheim Active Allocation Trust offering alongside Bank of America, Morgan Stanley, & Wells Fargo.

Laidlaw Capital Markets is pleased to have Co-Managed the $2,040,000 Blackrock ESG Capital Allocation Trust offering alongside Bank of America, Morgan Stanley, UBS, & Wells Fargo    

Laidlaw Capital Markets is pleased to have Lead Managed aTyr Pharma's (LIFE) $86,250,000. Offering alongside Piper Sandler and RBC. Read Article: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-pricing-75-million-public-offering-common

The Laidlaw Capital Markets team is pleased to announce our role as Sole Book-Runner and the pricing of a $10,000,000 Follow-on Offering for BioSig Technologies (BSGM). We are proud to have raised approximately $40,000,000 for [...]